Shares of Indaptus Therapeutics (INDP) slid 7.9% to $2.46 on July 8, extending a brutal 28% decline from $3.41 on June 26. The selloff reflects a convergence of existential financial pressures: a nearly depleted treasury, deeply discounted stock sales, and an upcoming shareholder vote that could reshape the company's capital structure — all while its core cancer-treatment program sits on ice.
The Cash Cupboard Is Nearly Bare
As of March 31, 2026, Indaptus had just $1.5 million in cash, down from $8.5 million at year-end 2025.
The company burned through $7.0 million in operating cash during Q1 alone , and raised zero dollars from financing activities in the quarter. At that burn rate, the company could not survive the summer without fresh money. Management has acknowledged it needs to raise additional capital, with "no assurance" it will come on acceptable terms, while it continues to assess financing alternatives and strategic options.
New Stock Sales Come at Fire-Sale Prices
In late June, Indaptus sold 20 million shares at just $0.60 apiece to overseas investors, raising roughly $12 million. That price was a fraction of where the stock traded at the time, signaling desperation to buyers. Now the company is seeking shareholder permission for something far larger: authorization to sell up to $300 million in private placements at prices between $0.60 and $1.00 per share — well below today's $2.46 quote. If approved at the July 28 annual meeting , that could flood the market with hundreds of millions of new shares against the current 113.2 million shares outstanding.
The Drug Pipeline Is Paused, Not Advancing
Indaptus has stopped enrollment in both its standalone and combination clinical trials of its lead immunotherapy candidate and has no current plans for new studies , while disclosing "substantial doubt" about its ability to continue as a going concern.
Its stated focus on finding a target company for a transaction effectively pivots the story away from an operating biotech — meaning shareholders aren't just buying dilution risk, they're buying a blank-check search for a new business.
One Investor Already Dominates the Board
David Lazar's December 2025 preferred-stock deal is convertible into 111 million common shares, giving him roughly 96.4% beneficial ownership on a fully diluted basis. Minority holders now face a company where one investor controls governance, clinical strategy is shelved, and every new financing round pushes their slice of the pie closer to zero.